RACHEL KLINE: Open Payments
NPI 1861070120 · STEWARDSON, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,867 in 93 payments from 35 companies in 2025. Trend: 2023 $0 · 2024 $2,837 · 2025 $1,867
Food & beverage: $1,836Education: $31
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 13 | $272 |
| Janssen Biotech, Inc. | 13 | $204 |
| E.R. Squibb & Sons, L.L.C. | 8 | $158 |
| GlaxoSmithKline, LLC. | 6 | $102 |
| Merck Sharp & Dohme LLC | 4 | $101 |
| Lilly USA, LLC | 4 | $88 |
| Celgene Corporation | 5 | $74 |
| PFIZER INC. | 3 | $69 |
| Daiichi Sankyo Inc. | 3 | $63 |
| AstraZeneca Pharmaceuticals LP | 3 | $58 |
Products named: OPDIVO, Fabhalta, KEYTRUDA, RYBREVANT, VERZENIO, ERLEADA, PLUVICTO, REBLOZYL.
Industry payments across IL — which companies pay providers there.
